DelveInsight’s "Polycystic Kidney Disease - Epidemiology Forecast, 2027” report provides a comprehensive analysis of the Polycystic Kidney Disease epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2027.
Markets Covered • United States • EU5 (Germany, France, Italy, Spain, and the United Kingdom) • Japan
Study Period: 2016-2027
Polycystic Kidney Disease Epidemiology The epidemiology section covers the historical, current as well as forecasted epidemiology for Polycystic Kidney Disease in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Polycystic Kidney Disease outlook. It also includes the explanation of changing trends of epidemiology outlining the Polycystic Kidney Disease scenario.
Polycystic Kidney Disease Epidemiology Segmentation The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Polycystic Kidney Disease thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.
Report Scope • The report covers detailed overview of Polycystic Kidney Disease explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns • It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan • The Polycystic Kidney Disease Report assesses the disease risk and burden and highlights the unmet needs • It also helps to recognize the growth opportunities in the 7MM with respect to the patient population
Key strengths • 10 Year Forecast • 7MM Coverage • Total Cases in Polycystic Kidney Disease
Key assessments • Patient Segmentation in Polycystic Kidney Disease • Polycystic Kidney Disease Risk & Burden • Factors driving growth in a specific Polycystic Kidney Disease patient population
Our reports have been used by over 10K customers, including:
T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Pipeline Review, H2 2018 Summary T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Cluster of differentiation 80 or CD80 or B7-1 is a protein...
Renal Diseases Drug Development Pipeline Review, 2018 Summary Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of the feet and ankles. The...
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 22.214.171.124) - Pipeline Review, H2 2018 Summary Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 126.96.36.199) - Glucokinase is an enzyme that catalyzes the initial step in utilization of glucose by the beta-cell and liver at physiological glucose...
The global demand for Angina (Angina Pectoris) treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Angina (Angina Pectoris) pipeline. Companies quickly adapting to the change and moving...
158 pages •
By Roots Analysis Private Ltd.
• Nov 2018
INTRODUCTION Chronic kidney disease (CKD) is characterized by progressive loss of kidney function over a period of time. In most patients suffering from CKD, symptoms (such as swollen ankles, blood in urine and foamy urine) are rarely observed until kidney function has declined by 75%. It is worth highlighting that over...
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Pipeline Review, H2 2018 Summary Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) pipeline Target constitutes close to 14 molecules. Out of which approximately 13 molecules are...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.